Susan Bobulsky, the Chief Commercial Officer at Adaptive Biotechnologies Corporation, has made a significant transaction involving the company's stock. According to a recent SEC filing, Bobulsky sold 6,444 shares of Adaptive Biotechnologies on October 6, 2026. This sale is notable as it was executed under a Rule 10b5-1 trading plan that Bobulsky adopted on December 16, 2025.
This transaction is important as it reflects ongoing changes in executive ownership at Adaptive Biotechnologies. Following the sale, Bobulsky now holds a total of 389,350 shares in the company. The filing indicates that the shares were sold at a price of $30.00 each, amounting to a total transaction value of $193,320.
Background
Adaptive Biotechnologies Corporation is a prominent player in the life sciences sector, specifically classified under the SIC code for biological products (no diagnostic substances). The company is based in Seattle, Washington, and is known for its innovative approaches in the field of immunology. Recently, Adaptive Biotechnologies has been involved in various filings, including Form 4 and Form 144 submissions, indicating active trading by its executives.
What the Filing Says
The SEC filing reveals that Bobulsky's sale of shares was part of a planned trading strategy. The filing states: "The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2025." This suggests that the sale was pre-scheduled and not a reaction to market conditions.
Impact
This sale may have implications for other executives and stakeholders within Adaptive Biotechnologies and the broader life sciences industry. As executives adjust their holdings, it can signal various strategic decisions or confidence levels in the company's future performance. Investors and analysts often scrutinize such transactions for insights into management's outlook.
What's Next
The filing does not say what happens next regarding further transactions or plans from Bobulsky or Adaptive Biotechnologies. Stakeholders will likely be attentive to any additional filings or announcements from the company in the coming weeks.